Inclusion Criteria:

          -  Histologic diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal
             cancer.

          -  Progressed within 6 months of completing at least 1 cycle of last platinum containing
             regimen. Patients with refractory disease (progression during platinum-containing
             therapy) are eligible. This includes both adjuvant therapy and in the recurrent
             setting.

          -  No more than 4 prior treatment regimens defined as investigational, chemotherapy,
             hormonal, biologic, or targeted therapy in the platinum resistant setting and total of
             7 prior regimens in all settings will be allowed. Prior maintenance therapy with
             biologic or targeted agent does NOT count as a treatment regimen (e.g. Maintenance
             bevacizumab, Parpi, or immunotherapy).

          -  At least one measurable lesion according to RECIST v1.1.

          -  For the eight patients enrolled for PK/PD. Availability of tissue from carcinoma. For
             most patients this will be archival tissue. If there is no archival tissue available,
             biopsy of lesion MUST be performed prior to initiation of therapy. Lesions must be
             available for biopsy as well in these patients.

          -  Any prior palliative radiation therapy must be completed at least 7 days prior to
             start of study treatment and patients must have recovered from any acute adverse
             effects prior to start of study treatment.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-1.

          -  Female patients who are not of childbearing potential and fertile female patients of
             childbearing potential who agree to use adequate contraceptive measures from 2 weeks
             prior to the study and until 1 month after study treatment discontinuation, who are
             not breastfeeding, and who have a negative serum or urine pregnancy test within 3 days
             prior to start of study treatment.

          -  Patients must have adequate (at baseline):

               1. Bone marrow function: Absolute neutrophil count (ANC) ≥1,500/µL. Platelets

                  ≥100,000/µL and hemoglobin > 8.0 gm/dL, transfusion allowed up to 1 week prior to
                  maintain Hgb >8.

               2. Renal function: Calculated creatinine clearance (CrCl) ≥35 mL/min/1.73 mm2

               3. Hepatic function: Bilirubin less than or equal to 1.5 x ULN; alkaline phosphatase
                  (AP), aspartate transaminase (AST) and alanine transaminase (ALT) less than or
                  equal to 3 x ULN. AP, AST and ALT less than or equal to 5 x ULN is acceptable if
                  patient has known hepatic metastasis

        Exclusion Criteria:

          -  Use of a study drug (approved or investigational drug therapy) ≤21 days or 5
             half-lives (whichever is shorter) prior to the first dose of study treatment. For
             study drugs for which 5 half-lives is ≤21 days, a minimum of 10 days between
             termination of the study drug and administration of current study treatment is
             required.

          -  Major surgical procedures ≤21 days of beginning study treatment, or minor surgical
             procedures ≤7 days. No waiting required following port-a-cath placement, ureteral
             stent placement, percutaneous nephrostomy tube placement.

          -  No other (chemotherapy, immunotherapy, hormonal anti-cancer therapy, radiotherapy
             [except for palliative local radiotherapy]), biological therapy or other novel agent
             is to be permitted while the patient is receiving study medications

          -  Grade >1 toxicity from prior therapy (except alopecia or anorexia or above hematologic
             criteria) unless controlled by medications.

          -  Inability to swallow oral medication. Note: Patient may not have a percutaneous
             endoscopic gastrostomy (PEG) tube or be receiving total parenteral nutrition (TPN) on
             this trial.

          -  Known malignant central nervous system disease other than neurologically stable,
             treated brain metastases - defined as metastasis having no evidence of progression
             after treatment for at least 4 weeks (including brain radiotherapy). Must be off any
             systemic corticosteroids for the treatment of brain metastases for at least 14 days
             prior to enrollment.

          -  Patient has had prescription or non-prescription drugs or other products (i.e.
             grapefruit juice) known to be moderate to strong inhibitors or inducers of CYP3A4,
             which cannot be discontinued 1 week prior to Day 1 of dosing and withheld throughout
             the study until 1 weeks after the last dose of study drug.

          -  Any known hypersensitivity or contraindication to the components of study treatment

          -  Pregnant or lactating

          -  Serious active infection at the time of enrollment, or another serious underlying
             medical condition at discretion of the enrolling physician that would impair the
             ability of the patient to receive study treatment. HIV or other immunodeficiency
             disease that is well controlled and that does not impact baseline lab values (i.e.
             outside of above noted parameters for inclusion) are NOT considered exclusion
             criteria.

          -  Presence of other active cancers other than ovarian cancer except those that do not
             require active therapy (i.e. on surveillance) and known non-invasive cancers and in
             situ cancers (e.g. non-melanoma skin cancers).

          -  Psychological, familial, sociological, or geographical conditions that do not permit
             compliance with the protocol.